| Phase 19 trials |
|
Phase 1
|
NCT06102902 |
Jun 2024 → Jan 2027 |
colorectal adenocarcinoma |
National Cancer Institute (NCI) |
Suspended
|
No outcome recorded
|
|
Phase 1
|
NCT06161493 |
Jan 2024 → Dec 2026 |
ovarian cancer |
Haider Mahdi |
Withdrawn
|
No outcome recorded
|
|
Phase 1
|
NCT05950464 |
Dec 2023 → Jun 2027 expected |
endometrial clear cell adenocarcinoma, endometrial endometrioid adenocarcinoma, ovarian clear cell adenocarcinoma, ovarian endometrioid adenocarcinoma +1 |
National Cancer Institute (NCI) |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT05803382 |
Nov 2023 → Jun 2027 expected |
colorectal carcinoma, metastatic malignant neoplasm |
National Cancer Institute (NCI) |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT05372640 |
Aug 2023 → Jun 2027 expected |
female breast carcinoma, invasive breast carcinoma, metastatic malignant neoplasm, nut midline carcinoma |
National Cancer Institute (NCI) |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT05422794 |
May 2023 → Mar 2027 expected |
female breast carcinoma, triple-negative breast carcinoma |
National Cancer Institute (NCI) |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT05111561 |
Aug 2022 → Mar 2027 |
metastatic malignant neoplasm, triple-negative breast carcinoma |
National Cancer Institute (NCI) |
Suspended
|
No outcome recorded
|
|
Phase 1
|
NCT04840589 |
Feb 2022 → Sep 2028 |
metastatic malignant neoplasm, ovarian carcinoma |
National Cancer Institute (NCI) |
Suspended
|
No outcome recorded
|
|
Phase 1
|
NCT02705469 |
May 2016 → Oct 2017 |
castration-resistant prostate carcinoma |
Zenith Epigenetics |
Completed
|
No outcome recorded
|
| Phase 1/24 trials |
|
Phase 1/2
|
NCT05053971 |
Nov 2022 → Jul 2027 expected |
digestive system carcinoma, metastatic carcinoma, refractory malignant neoplasm |
National Cancer Institute (NCI) |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT05019716 |
Jul 2022 → Jun 2026 overdue |
nut midline carcinoma |
National Cancer Institute (NCI) |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT04145375 |
Nov 2019 → Dec 2027 expected |
castration-resistant prostate carcinoma |
Zenith Epigenetics |
Enrolling by invitation
|
No outcome recorded
|
|
Phase 1/2
|
NCT02711956 |
Dec 2016 → Nov 2019 |
castration-resistant prostate carcinoma |
Zenith Epigenetics |
Completed
|
No outcome recorded
|
| Phase 28 trials |
|
Phase 2
|
NCT05253131 |
Nov 2026 → Nov 2031 expected |
malignant peripheral nerve sheath tumor, neurofibromatosis type 1 |
University of Alabama at Birmingham |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06922318 |
Aug 2025 → Aug 2031 expected |
castration-resistant prostate carcinoma |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05071937 |
Apr 2023 → Nov 2033 expected |
fallopian tube cancer, ovarian cancer, peritoneum cancer |
Alexander B Olawaiye, MD |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05327010 |
Nov 2022 → Dec 2026 expected |
metastatic malignant neoplasm |
National Cancer Institute (NCI) |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05607108 |
Nov 2022 → Nov 2027 expected |
squamous cell lung carcinoma |
Memorial Sloan Kettering Cancer Center |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT04986423 |
Sep 2021 → Dec 2026 expected |
castration-resistant prostate carcinoma |
Zenith Epigenetics |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT04471974 |
Jan 2021 → May 2028 expected |
castration-resistant prostate carcinoma, prostate adenocarcinoma, prostate small cell carcinoma |
Rahul Aggarwal |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT03901469 |
Jun 2019 → Mar 2024 |
triple-negative breast carcinoma |
Zenith Epigenetics |
Terminated
|
No outcome recorded
|